SL-325, the first DR3-blocking antibody in humans, enters Phase 2b in Crohn's disease — endoscopic response at Week 12 is the make-or-break read

Bull

A positive readout would show statistically significant endoscopic response at Week 12 versus placebo in both or the high-dose SL-325 arm, with a clinically meaningful effect size (e.g., ≥20–25 percentage point separation), ideally accompanied by clinical remission signal on the key secondary endpoint. This would establish proof-of-concept for DR3 blockade as a mechanism in Crohn's disease, differentiate SL-325 from existing approved biologics on a novel pathway, and provide a strong foundation for a pivotal program and potential partnership or licensing interest.

Bear

Failure modes include an absence of statistically significant endoscopic response separation from placebo at Week 12, which would suggest the DR3/TL1A axis is not a sufficiently dominant driver of mucosal inflammation in this population. A high placebo response rate — historically problematic in Crohn's disease trials — could obscure a real drug effect, while dose selection errors (insufficient exposure at both doses) or patient enrichment failure (inadequate baseline endoscopic disease activity) could produce a null result that does not cleanly refute the mechanism but still terminates the program commercially.